McCormick, FTC in talks to settle spice price lawsuit

Article Abstract:

McCormick and Company Inc is in the process of negotiating a settlement with the US Federal Trade Commission (FTC) on allegations of price discrimination in an effort to avoid a costly legal battle. The agency was set to file a lawsuit against McCormick after finding out that it paid large fees that amounted to discounts to only some retailers. After reviewing 2,200 of McCormick's contracts for nearly three years, the FTC found three instances of violations of the Robinson-Patman Act.

Spices, McCormick and Company Inc. (Sparks, Maryland)

---

Vitamin makers to settle

Article Abstract:

Seven vitamin producers are expected to agree to a $1.05-billion settlement of an antitrust class-action lawsuit that charged them of price-fixing. The companies involved are Hoffmann-La Roche AG, BASF AG, Rhone-Poulenc SA, Hoechst Marion Roussel Inc, Daiichi Corp, Eisai Company Ltd and Takeda, all of which were alleged of a global conspiracy to increase prices and allocate market shares for bulk vitamins.

Pharmaceutical Preparation Manufacturing, Vitamin Preparations

---

FTC may sue McCormick over spice prices

Article Abstract:

McCormick and Co faces an antitrust lawsuit that would accuse the spice manufacturer of selectively giving discounts. Staff attorneys at the Federal Trade Commission have recommended filing a suit against the company, which they found to have been paying hefty fees to assure shelf space in some stores. The Robinson-Pactman ACt, a Depression-era legislation, prohibits manufacturers from imposing different prices to different retailers.

Government regulation (cont), McCormick and Co.

Similar abstracts:

• Abstracts: Visto hits Microsoft with lawsuit over wireless e-mail services. Microsoft breakup closer to becoming reality
• Abstracts: Microsoft mediation talks sputter as deadline looms. Congress takes sides on Microsoft ruling
• Abstracts: Microsoft findings spur lawsuit filings. Microsoft CEO plays to win. Microsoft's Gates steps aside as CEO
• Abstracts: Drug merger turns into tense triangle. Drug firms polish merger. $80 billion drug merger talks back on

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.